Tenon Medical entered into a warrant inducement agreement on September 11, 2026, with an institutional investor to exercise outstanding Series A warrants for 572,179 shares at $5.02 per share, generating approximately $2.87 million in gross proceeds. In exchange, the company issued new unregistered five-year Series B warrants to purchase up to 858,269 shares (150% of the underlying shares) at an exercise price of $5.02 per share. The transaction closed on September 14, 2026, with proceeds designated for working capital and general corporate purposes. WallachBeth Capital LLC served as financial advisor, receiving a 7% fee plus up to $65,000 in reimbursable expenses. Tenon Medical is a medical device company specializing in minimally invasive surgical systems for sacroiliac joint fusion.

Tenon Medical, Inc. repaid in full its outstanding original issue discount senior convertible promissory notes with an aggregate principal balance of approximately $5.16 million ahead of their September 11, 2026 maturity date. The company stated this proactive repayment strengthens its balance sheet and eliminates potential dilution from converting the notes into common stock at a discount to market prices. Tenon Medical is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders.

Tenon Medical, Inc. closed a private placement on August 31, 2026, raising gross proceeds of $2,999,404.59 from the sale of pre-funded warrants and Series A warrants to an institutional investor. The transaction involved issuing 597,610 shares underlying pre-funded warrants at $5.019 per unit and 1,058,517 Series A warrants exercisable at $5.02 per share. WallachBeth Capital LLC served as the exclusive placement agent, receiving a 7% fee plus expenses. The company intends to use net proceeds for debt repayment, working capital, and general corporate purposes. Tenon Medical operates in the medical device industry, developing systems for sacro-pelvic disorders.

Tenon Medical reported second quarter 2026 revenue of $1.3 million, a 127% increase year-over-year, with gross profit rising to $0.8 million and gross margin improving to 64%. The company posted a net loss of $4.1 million, or $12.35 per share. Subsequent to the quarter end, Tenon closed a public offering for $4.2 million in gross proceeds on July 1, 2026, and received FDA 510(k) clearance for its updated Catamaran SI Joint Fusion System on July 2, 2026. Additionally, the company effected a 1-for-35 reverse stock split on August 10, 2026, to regain Nasdaq compliance. Tenon Medical is a medical device company focused on treating sacro-pelvic disorders.

Tenon Medical, Inc. filed a Certificate of Amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware on August 6, 2026, effecting a 1-for-35 reverse stock split of its common stock. The transaction became effective at 12:01 a.m. Eastern Time on August 10, 2026, following shareholder approval at the July 23, 2026 annual meeting. Every thirty-five shares were combined into one share, with fractional entitlements rounded up to the next whole number and no cash paid for fractions. The split aims to meet Nasdaq Capital Market's minimum $1.00 average closing price requirement for continued listing. Proportionate adjustments were made to exercise prices and share counts for outstanding stock options, warrants, and restricted stock units. Tenon Medical is a medical device company dedicated to transforming care for patients with sacro-pelvic disorders.

Tenon Medical, Inc. held its 2026 Annual Meeting of Stockholders on July 23, 2026, where shareholders approved several key proposals. These included the election of seven directors, the ratification of Haskell & Whitee LLP as the independent auditor, and authorization for the Board to implement a reverse stock split with a ratio ranging from 1-for-2 to 1-for-35. Additionally, stockholders approved proposals regarding the issuance of common stock underlying convertible promissory notes from a March 2026 debt financing and rules governing future financings to comply with Nasdaq listing requirements. Tenon Medical, Inc. is a medical technology company.